Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum (2022)
- Authors:
- USP affiliated authors: ARAUJO, GABRIEL LIMA BARROS DE - FCF ; KANASHIRO, EDITE HATSUMI YAMASHIRO - IMT ; FREITAS, VÉRA LÚCIA TEIXEIRA DE - FM ; CHACRA, NÁDIA ARACI BOU - FCF ; ELIODORO, RAISSA HELOISA DE ARAUJO - IMT ; BARBOSA, EDUARDO JOSÉ - FCF
- Unidades: FCF; IMT; FM
- DOI: 10.1016/j.ejps.2021.106097
- Subjects: LIPÍDEOS; LEISHMANIOSE VISCERAL; DOENÇAS NEGLIGENCIADAS; NANOTECNOLOGIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Pharmaceutical Sciences
- ISSN: 0928-0987
- Volume/Número/Paginação/Ano: v. 169, p. 1-11 art. 106097, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
MONTEIRO, Lis Marie et al. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, v. 169, p. 1-11 art. 106097, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2021.106097. Acesso em: 04 out. 2024. -
APA
Monteiro, L. M., Löbenberg, R., Barbosa, E. J., Araujo, G. L. B. de, Sato, P. K., Kanashiro, E. H. Y., et al. (2022). Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 169, 1-11 art. 106097. doi:10.1016/j.ejps.2021.106097 -
NLM
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 out. 04 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097 -
Vancouver
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 out. 04 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097 - Innovative drug delivery systems for leprosy treatment
- Physical chemical properties of furosemide nanocrystals developed using rotation revolution mixer
- Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
- Innovative approach to treatment of ocular tuberculosis: cationic Nanoemulsion
- Thermal study, process optimization, and water solubility improvement of a freeze-dried artemether nanosuspension for malaria treatment
- Innovative pharmaceutical strategies for niclosamide repositioning
- Nanoemulsão contendo niclosamida: preparação, caracterização físico-química e avaliação da atividade anticâncer in vitro
- Hot-melt extrudability of amorphous solid dispersions of flubendazole-copovidone: an exploratory study of the effect of drug loading and the balance of adjuvants on extrudability and dissolution
- A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis
- Nanomaterials for hair care applications
Informações sobre o DOI: 10.1016/j.ejps.2021.106097 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 3056138.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
